SBIR/STTR Research Award

SBIR Phase I:Monitoring and Treatment of Urinary Incontinence in Women

Award identifier 24278a7cc925d7b12bbf4e9f215a87c10178af61eaba22c5f355bef73946c7a4Awarding agency National Science Foundation

Award amount

$255,078

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
LIV LABS INC
Proposal award date
2022-01-15
Contract end date
2023-07-31
UEI
XBM9L92LT4D1
Solicitation number
NSF 21-563
Topic code
DH

Research abstract

The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve care for the 27 million American women with involuntary urine leakage. Such leakage is highly prevalent, affecting one in three adult women and worsening with age. Most women avoid medical treatment, either because they accept their leakage as natural or hold an unfavorable view of treatments like surgery and pelvic floor physical therapy. This research will explore a scalable, high-tech approach to at-home treatments recommended by clinicians. Patients will interact virtually with health coaches and routinely receive personalized, semi-automated help and encouragement. Health coaches will be able to monitor the simultaneous progress of many patients remotely. Benefits include (1) helping more women at lower cost versus current practice and (2) increasing clinician productivity. It could save individual women up to $1,000 annually and eliminate tens of thousands of unnecessary surgeries.This Small Business Innovation Research (SBIR) Phase I project will develop a healthcare system workflow technology enabled by AI algorithms for tailoring an incontinence home health intervention to a wide variety of patient needs, preferences, and idiosyncratic behaviors. Study use cases will include medical device usage training and exercise regimen adherence. To address these scenarios, researchers will create a clinically-valid, user-specific, dynamic incontinence treatment solution comprising a mobile app for symptomatic women and a health coaching platform that integrates user data and generates tailored interactions. Solution elements will be built to (1) collect and manage high quantities of rich user data, (2) develop and train real-time inference algorithms, and (3) incorporate machine learning approaches to learn from user responses to system outputs (feedback, recommendations, encouragement, etc.). Known principles of health behavior change will be incorporated in adapting interactions for users.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $2,492,073. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.